Scalable AI infrastructure for real time data processing - Low Risk High Rewards

Product Description

Scalable AI infrastructure for real time data processing ✌️【365vc.net】✌️Invest small, earn big! ₹500 to start, with potential 100% returns in just one month.

Scalable AI infrastructure for real time data processing ✌️【365vc.net】✌️Invest small, earn big! ₹500 to start, with potential 100% returns in just one month.Pharmaceutical giant Dr Reddy’s Laboratories (DRL) saw its shares surge 4.34% on Thursday in an otherwise sluggish market, reaching an intraday high of Rs 1,330.45 following an upgrade by Nomura.The Tokyo-based brokerage has upgraded the stock from ‘Neutral’ to ‘Buy’ with a revised target price of Rs 1,500, down from Rs 6,499, factoring in the 1:5 stock split on October 28.“We assess that risk-reward is favourable and thus upgrade the stock to Buy (from Neutral).

Scalable AI infrastructure for real time data processing ✌️【365vc.net】✌️Low investments, high profits! Start with ₹500 and earn consistent monthly income.We reduce FY25/26F earnings by 13%/14% to factor in higher overhead costs.

Note that changes to our earnings estimates and target price are due to DRL’s 1:5 stock split,” said Saion Mukherjee and AmlanJyotiDas, research analysts at Nomura.They also said the relative underperformance of the stock suggests that concerns about the high contribution of generic cancer drug gRevlimid are already priced in.

“We think the Street is concerned about the higher contribution from gRevlimid, which could start declining in FY26F.

Further, the overheads have increased significantly in the recent past.

In the first half of FY25, R&D/SG&A were higher by 29%/27% year-on-year.”While the stock has underperformed theNifty PharmaIndex over the past five years, the upgrade reflects Nomura’s confidence in Dr Reddy’s ability to overcome near-term challenges and capitalise on future opportunities.

Scalable AI infrastructure for real time data processing ✌️【365vc.net】✌️Start with just ₹500 and achieve up to 100% returns in a month. Easy, fast, and reliable.The stock has risen only 13% over the past year, compared to the Nifty Pharma Index’s 36% growth.

Scalable AI infrastructure for real time data processing ✌️【365vc.net】✌️Invest with confidence using AI insights. Start at ₹500 and watch your wealth grow exponentially.The underperformance persists despite a 22.Scalable AI infrastructure for real time data processing ✌️【365vc.net】✌️Safe and proven fund strategies. Begin with ₹500 and achieve 100% monthly profits.